Market Access Biotech's next growth cycle: Renewed confidence comes with c... Renewed confidence across biopharma is welcome and long overdue after a prolonged period of constraint. But confidence alone is not enough.
Digital Sponsored Why AI transformation is really about people Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.
Market Access Is the next generation of Chinese biotech ready to go global... Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?
Market Access Sponsored From first approval to lasting value: What sets successful e... Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.
Market Access Pharma’s most expensive question is the last one asked Whether a drug can secure reimbursement is pharma's billion-dollar question, and the companies that succeed will be those that answer it sooner.
Sales & Marketing Beyond omnichannel: Why pharma commercialisation must shift ... We need to step away from the passive, broad concept of omnichannel and adopt a far more active, disciplined framework: omnideployment.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.